AEMD
Aethlon Medical, Inc. NASDAQ Listed Mar 4, 1999$0.71
-6.07%
vs $0.76
Mkt Cap $540.6K
52w Low $0.65
0.2% of range
52w High $27.40
50d MA $1.97
200d MA $3.25
P/E (TTM)
—
EV/EBITDA
—
P/B
0.0x
Debt/Equity
0.1x
ROE
-203.4%
P/FCF
-0.0x
RSI (14)
8.40
ATR (14)
$0.17
Beta
1.52
50d MA
$1.97
200d MA
$3.25
Avg Volume
1.2M
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
11555 Sorrento Valley Road · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | AMC | -2.46 | 4.08 | +265.9% | 2.02 | -4.5% | -5.9% | +6.3% | -1.0% | -3.5% | -1.0% | — |
| Feb 12, 2026 | AMC | -2.01 | -2.45 | -21.9% | 1.98 | -1.0% | -1.0% | +8.2% | -1.4% | -2.4% | -1.5% | — |
| Nov 12, 2025 | AMC | -1.70 | -3.74 | -120.0% | 4.20 | +1.9% | +12.9% | +4.4% | -18.2% | +3.7% | -10.2% | — |
| Aug 13, 2025 | AMC | -6.80 | -8.50 | -25.0% | 12.30 | +1.6% | -4.9% | -2.6% | +2.6% | -3.4% | -1.8% | — |
| Jun 26, 2025 | AMC | -0.98 | -7.28 | -642.9% | 19.40 | -24.2% | -35.6% | -4.0% | -1.7% | +5.1% | +0.0% | — |
| Feb 12, 2025 | AMC | -0.22 | -0.13 | +40.9% | 53.40 | -2.6% | -5.4% | -2.6% | +4.1% | -2.3% | -2.6% | — |
| Nov 13, 2024 | AMC | -0.20 | -0.20 | +0.0% | 32.50 | -1.5% | -1.8% | +0.0% | -2.8% | +0.3% | +0.3% | — |
| Aug 14, 2024 | AMC | -0.44 | -0.34 | +22.7% | 30.80 | -13.6% | -16.9% | +26.6% | +14.2% | +0.5% | +21.5% | — |
| Jun 27, 2024 | AMC | -1.18 | -0.91 | +22.9% | 46.30 | -8.9% | -13.8% | -9.8% | -7.2% | -4.2% | +12.5% | — |
| Feb 14, 2024 | AMC | -1.23 | -1.37 | -11.4% | 138.40 | -1.2% | -5.2% | +1.8% | -1.2% | +3.0% | +0.6% | — |
| Nov 14, 2023 | AMC | -1.35 | -1.22 | +9.6% | 132.80 | -0.6% | +7.2% | -2.8% | -5.8% | +4.3% | -1.2% | — |
| Aug 10, 2023 | AMC | -1.20 | -1.30 | -8.3% | 280.00 | -5.7% | -2.9% | +0.0% | -5.9% | -3.1% | -6.5% | — |
| Jun 28, 2023 | AMC | -1.60 | -1.10 | +31.2% | 336.00 | +2.4% | -4.8% | -10.0% | -2.8% | -2.9% | +26.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $12.30 | $12.50 | +1.6% | -4.9% | -2.6% | +2.6% | -3.4% | -1.8% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.90 | $35.30 | +1.1% | -5.4% | +9.1% | -7.8% | +1.8% | -11.5% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.20 | $50.80 | -0.8% | -2.3% | -2.6% | -4.1% | -2.8% | +0.0% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.30 | $58.20 | -1.9% | -1.2% | -4.4% | -4.6% | +4.9% | +8.6% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.90 | $30.90 | -3.1% | +0.0% | -2.8% | +0.3% | +0.3% | -1.3% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.90 | $46.10 | -3.8% | +4.8% | -0.4% | -6.4% | -1.1% | -13.8% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $139.20 | $139.20 | +0.0% | -5.2% | +4.8% | -0.6% | -1.2% | -0.6% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $115.20 | $113.60 | -1.4% | +2.8% | +0.7% | +1.3% | -2.6% | -2.0% |
| Nov 15 | Maxim Group | Downgrade | Buy → Hold | — | $400.00 | $400.00 | +0.0% | -8.0% | -2.2% | -2.2% | -4.5% | -2.4% |
| Nov 14 | Maxim Group | Downgrade | Buy → Hold | — | $400.00 | $400.00 | +0.0% | +0.0% | -8.0% | -2.2% | -2.2% | -4.5% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4264.00 | $4112.00 | -3.6% | -3.9% | +1.0% | -1.5% | -3.3% | +1.8% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4320.00 | $4400.00 | +1.9% | -1.3% | -3.9% | +1.0% | -1.5% | -3.3% |
| Jun 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1392.00 | $1600.00 | +14.9% | +34.5% | +0.0% | -1.7% | -3.9% | -0.5% |
| Jan 8 | Maxim Group | Maintains | Buy → Buy | — | $2040.00 | $2096.00 | +2.7% | +6.3% | +0.4% | -8.1% | +4.0% | +0.8% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $1240.00 | $1352.00 | +9.0% | +9.7% | +7.1% | +2.2% | -7.5% | +11.6% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11640.00 | $12360.00 | +6.2% | +7.2% | +0.0% | +1.0% | +1.9% | -0.9% |
| Nov 20 | H.C. Wainwright | Maintains | Buy → Buy | — | $11640.00 | $12360.00 | +6.2% | +7.2% | +0.0% | +1.0% | +1.9% | -0.9% |
No insider trades available.
8-K · 2.02
!! High
Aethlon Medical, Inc. -- 8-K 2.02: Earnings Results
Aethlon Medical reported earnings results, though the filing provides no specific financial metrics or performance details to assess whether results met or missed expectations.
Jun 10
8-K · 8.01
!! High
Aethlon Medical, Inc. -- 8-K 8.01: Material Event / Announcement
Aethlon Medical activated its S-3 registration statement to conduct a registered offering, enabling the company to raise capital efficiently through a streamlined process with reduced disclosure requirements.
Jun 4
8-K
Unknown — 8-K Filing
This 8-K filing indicates AEMD maintains emerging growth company status, likely exempting it from certain regulatory burdens and offering compliance flexibility that could temporarily support margins until scaling requires full compliance.
Mar 17
8-K · 5.02
!!! Very High
AETHLON MEDICAL INC -- 8-K 5.02: Executive Change
Chief executive departure signals internal instability at this micro-cap medical device company, creating uncertainty about strategic direction and increasing execution risk for shareholders.
Feb 23
8-K · 7.01
! Medium
AETHLON MEDICAL INC -- 8-K 7.01: Regulation FD Disclosure
Aethlon Medical disclosed material non-public information to select parties, potentially signaling upcoming news that could significantly impact AEMD's stock price once publicly released.
Feb 12
Valuation
Market Cap
$541K
Enterprise Value
-$5.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.02x
P/S
—
P/FCF
-0.01x
EV/EBITDA
—
Shares Out
156K
Financials (TTM)
Revenue
$0
Net Income
-$7.2M
EBITDA
-$6.7M
Free Cash Flow
-$7.6M
Op Cash Flow
-$7.6M
EPS Basic
$-85.80
EPS Diluted
$-15.89
EPS Forward
$-2.21
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.4M
Total Liab.
$2.2M
Total Equity
$5.1M
Cash
$5.5M
LT Debt
$0
Book Value/Sh
$32.83
Debt/Equity
0.13x
Current Ratio
3.13
Quick Ratio
3.13
Returns & Growth
ROE
-203.4%
ROA
-169.4%
ROIC
-161.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
-76.5%
Price Returns
2W
-62.8%
1M
-66.2%
3M
-66.7%
6M
-74.8%
12M
-94.3%
Technicals
52W High
$27.40
52W Low
$0.65
50d MA
$1.97
200d MA
$3.25
RSI (14)
8.40
ATR (14)
$0.17
Beta
1.52
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 4:16pm
· Source: financialmodelingprep.com